A Drosophila model of prion disease and its metabolic changes in the brain

Abstract

Background: Prion diseases (PrDs) are fatal transmissible neurodegenerative disorders caused by misfolded prion protein, which is highly expressed in the brain. Drosophila has been employed as a model system for studying mammalian neurodegenerative diseases.

Methods: Drosophila transgenic for hamster prion protein (HaPrP) was generated by Valium20 transformation. Locomotion, longevity, protease resistance, and histology were assessed, and nontargeted metabolomics analyses were performed to investigate the changes in Drosophila metabolism with the HaPrP expression and metformin treatment.

Results: The Drosophila model exhibited pan-neuronal expression of HaPrP, with expression levels increasing with age. Flies displayed reduced climbing ability, shortened lifespan, and vacuolar structures in the brain. Additionally, HaPrP expressed in older flies demonstrated resistance to digestion by 5 μg/mL Proteinase K. The Drosophila model also displayed alterations in protein, lipid, and carbohydrate metabolism. We hypothesize that glutamate, N-acetylaspartate, ceramide, phosphatidylethanolamine, dihydroxyacetone phosphate, ribose-5-phosphate, and pyruvate are key metabolites potentially related to PrDs. Metformin improved locomotor activity, reduced PrP^res formation, and ameliorated mitochondrial dysfunction in flies, which may be associated with alterations in succinate, pyruvate, choline, and sphingomyelin levels.

Conclusions: We generated a Drosophila model of PrDs that recapitulates key pathological features observed in mammals. Preliminary applications have demonstrated that the Drosophila model is suitable for PrDs research and the high-throughput screening of potential therapeutic compounds.

Keywords

disease model / Drosophila / metabolism / prion

References

[1] Prusiner SB. Molecular biology and pathogenesis of prion diseases. Trends Biochem Sci. 1996; 21(12): 482-487.

[2] Sigurdson CJ, Bartz JC, Glatzel M. Cellular and molecular mechanisms of prion disease. Annu Rev Pathol. 2019; 14: 497-516.

[3] Wen P, Sun Z, Yang D, et al. Irisin regulates oxidative stress and mitochondrial dysfunction through the UCP2-AMPK pathway in prion diseases. Cell Death Dis. 2025; 16(1): 66.

[4] Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998; 95(23): 13363-13383.

[5] Yu Y, Fedele G, Celardo I, Loh SHY, Martins LM. Parp mutations protect from mitochondrial toxicity in Alzheimer's disease. Cell Death Dis. 2021; 12(7): 651.

[6] Issa AR, Sun J, Petitgas C, et al. The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the drosophila brain. Autophagy. 2018; 14(11): 1898-1910.

[7] Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019; 575(7781): 203-209.

[8] Markmiller S, Soltanieh S, Server KL, et al. Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell. 2018; 172(3): 590-604.e13.

[9] McGurk L, Berson A, Bonini NM. Drosophila as an in vivo model for human neurodegenerative disease. Genetics. 2015; 201(2): 377-402.

[10] Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genet. 2018; 19(7): 405-418.

[11] Fernandez-Funez P, Sanchez-Garcia J, Rincon-Limas DE. Drosophila models of prionopathies: insight into prion protein function, transmission, and neurotoxicity. Curr Opin Genet Dev. 2017; 44: 141-148.

[12] Yang Q, Gong ZJ, Zhou Y, et al. Role of drosophila alkaline ceramidase (Dacer) in drosophila development and longevity. Cell Mol Life Sci. 2010; 67(9): 1477-1490.

[13] Jung S, Kim S, Seo Y, Lee S. Metabolic alterations associated with γ-Hydroxybutyric acid and the potential of metabolites as biomarkers of its exposure. Metabolites. 2021; 11(2).

[14] Bourgognon JM, Spiers JG, Scheiblich H, et al. Alterations in neuronal metabolism contribute to the pathogenesis of prion disease. Cell Death Differ. 2018; 25(8): 1408-1425.

[15] Ni JQ, Zhou R, Czech B, et al. A genome-scale shRNA resource for transgenic RNAi in drosophila. Nat Methods. 2011; 8(5): 405-407.

[16] Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023; 19(8): 460-476.

[17] Cao G, Gong T, Du Y, Wang Y, Ge T, Liu J. Mechanism of metformin regulation in central nervous system: progression and future perspectives. Biomed Pharmacother. 2022; 156: 113686.

[18] Demare S, Kothari A, Calcutt NA, Fernyhough P. Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system. Expert Rev Neurother. 2021; 21(1): 45-63.

[19] Abdelaziz DH, Thapa S, Abdulrahman B, Vankuppeveld L, Schatzl HM. Metformin reduces prion infection in neuronal cells by enhancing autophagy. Biochem Biophys Res Commun. 2020; 523(2): 423-428.

[20] Thapa S, Abdelaziz DH, Abdulrahman BA, Schatzl HM. Sephin1 reduces prion infection in prion-infected cells and animal model. Mol Neurobiol. 2020; 57(5): 2206-2219.

[21] Lehmann S, Costa AC, Celardo I, Loh SH, Martins LM. Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis. 2016; 7(3): e2166.

[22] Tufi R, Gandhi S, de Castro IP, et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat Cell Biol. 2014; 16(2): 157-166.

[23] Costa AC, Loh SH, Martins LM. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. Cell Death Dis. 2013; 4(1): e467.

[24] Thackray AM, Muhammad F, Zhang C, et al. Ovine PrP transgenic drosophila show reduced locomotor activity and decreased survival. Biochem J. 2012; 444(3): 487-495.

[25] Fernandez-Funez P, Casas-Tinto S, Zhang Y, et al. In vivo generation of neurotoxic prion protein: role for hsp70 in accumulation of misfolded isoforms. PLoS Genet. 2009; 5(6): e1000507.

[26] Thackray AM, Di Y, Zhang C, et al. Prion-induced and spontaneous formation of transmissible toxicity in PrP transgenic drosophila. Biochem J. 2014; 463(1): 31-40.

[27] Thackray AM, Lam B, McNulty EE, et al. Clearance of variant Creutzfeldt-Jakob disease prions in vivo by the Hsp70 disaggregase system. Brain. 2022; 145(9): 3236-3249.

[28] Zhao M, Li J, Li Z, et al. SIRT1 regulates mitochondrial damage in N2a cells treated with the prion protein fragment 106-126 via PGC-1α-TFAM-mediated mitochondrial biogenesis. Int J Mol Sci. 2024; 25(17).

[29] Wu JS, Luo L. A protocol for dissecting Drosophila melanogaster brains for live imaging or immunostaining. Nat Protoc. 2006; 1(4): 2110-2115.

[30] Madabattula ST, Strautman JC, Bysice AM, et al. Quantitative analysis of climbing defects in a drosophila model of neurodegenerative disorders. J Vis Exp. 2015; 100: e52741.

[31] Dhar G, Mukherjee S, Nayak N, et al. Various behavioural assays to detect the neuronal abnormality in flies. In: Mishra M, ed. Fundamental Approaches to Screen Abnormalities in Drosophila. Springer US; 2020: 223-251.

[32] Deng JLN. The lifespan test of drosophila. Bio-101. 2019; 2019: e1010255.

[33] Karmakar P, Mishra M. Histological analysis of the drosophila head with special reference to the eye and brain. In: Mishra M, ed. Fundamental Approaches to Screen Abnormalities in Drosophila. Springer US; 2020: 39-49.

[34] Budka H. Neuropathology of prion diseases. Br Med Bull. 2003; 66: 121-130.

[35] Liu H, Chen Y, Ming D, et al. Integrative analysis of indirect calorimetry and metabolomics profiling reveals alterations in energy metabolism between fed and fasted pigs. J Anim Sci Biotechnol. 2018; 9: 41.

[36] Herzog C, Sales N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet. 2004; 363(9407): 422-428.

[37] Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995; 83(1): 79-90.

[38] Ducrot C, Arnold M, de Koeijer A, Heim D, Calavas D. Review on the epidemiology and dynamics of BSE epidemics. Vet Res. 2008; 39(4): 15.

[39] Wells GA, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec. 1987; 121(18): 419-420.

[40] Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993; 73(7): 1339-1347.

[41] Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA. 1993; 90(22): 10608-10612.

[42] Raeber AJ, Muramoto T, Kornberg TB, Prusiner SB. Expression and targeting of Syrian hamster prion protein induced by heat shock in transgenic Drosophila melanogaster. Mech Dev. 1995; 51(2-3): 317-327.

[43] Deleault NR, Dolph PJ, Feany MB, et al. Post-transcriptional suppression of pathogenic prion protein expression in drosophila neurons. J Neurochem. 2003; 85(6): 1614-1623.

[44] Thackray AM, McNulty EE, Nalls AV, et al. Genetic modulation of CWD prion propagation in cervid PrP drosophila. Biochem J. 2023; 480(19): 1485-1501.

[45] Altmann F, Staudacher E, Wilson IB, Marz L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J. 1999; 16(2): 109-123.

[46] Adle-Biassette H, Verney C, Peoc'h K, et al. Immunohistochemical expression of prion protein (PrPC) in the human forebrain during development. J Neuropathol Exp Neurol. 2006; 65(7): 698-706.

[47] Sales N, Hassig R, Rodolfo K, et al. Developmental expression of the cellular prion protein in elongating axons. Eur J Neurosci. 2002; 15(7): 1163-1177.

[48] Fernandez-Funez P, Zhang Y, Casas-Tinto S, Xiao X, Zou W-Q, Rincon-Limas DE. Sequence-dependent prion protein Misfolding and neurotoxicity. J Biol Chem. 2010; 285(47): 36897-36908.

[49] Mercer RCC, Harris DA. Mechanisms of prion-induced toxicity. Cell Tissue Res. 2023; 392(1): 81-96.

[50] Liberski PP, Sikorska B, Bratosiewicz-Wasik J, Gajdusek DC, Brown P. Neuronal cell death in transmissible spongiform encephalopathies (prion diseases) revisited: from apoptosis to autophagy. Int J Biochem Cell Biol. 2004; 36(12): 2473-2490.

[51] Kovacs GG, Budka H. Prion diseases: from protein to cell pathology. Am J Pathol. 2008; 172(3): 555-565.

[52] Soto C, Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol Med. 2011; 17(1): 14-24.

[53] Thackray AM, Muhammad F, Zhang C, et al. Prion-induced toxicity in PrP transgenic drosophila. Exp Mol Pathol. 2012; 92(2): 194-201.

[54] Jodeiri Farshbaf M, Kiani-Esfahani A. Succinate dehydrogenase: prospect for neurodegenerative diseases. Mitochondrion. 2018; 42: 77-83.

[55] Noda M. Dysfunction of glutamate receptors in microglia may cause neurodegeneration. Curr Alzheimer Res. 2016; 13(4): 381-386.

[56] Domercq M, Vazquez-Villoldo N, Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci. 2013; 7: 49.

[57] Liu H, Leak RK, Hu X. Neurotransmitter receptors on microglia. Stroke Vasc Neurol. 2016; 1(2): 52-58.

[58] Katsumoto A, Takeuchi H, Takahashi K, Tanaka F. Microglia in Alzheimer's disease: risk factors and inflammation. Front Neurol. 2018; 9: 978.

[59] Zhang X, Wang D, Zhang B, Zhu J, Zhou Z, Cui L. Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. Drug Discov Today. 2020; 25(6): 1074-1085.

[60] Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020; 19(9): 609-633.

[61] Virarkar M, Alappat L, Bradford PG, Awad AB. l-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit Rev Food Sci Nutr. 2013; 53(11): 1157-1167.

[62] Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist. 2010; 16(4): 435-452.

[63] Bodineau C, Tome M, Courtois S, et al. Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis. Nat Commun. 2021; 12(1): 4814.

[64] Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun. 2016; 7: 11457.

[65] Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014; 71(14): 2577-2604.

[66] Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci. 2009; 16(1): 63.

[67] Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010; 2(52): 52ra73.

[68] Orozco JM, Krawczyk PA, Scaria SM, et al. Dihydroxyacetone phosphate signals glucose availability to mTORC1. Nat Metab. 2020; 2(9): 893-901.

[69] Stincone A, Prigione A, Cramer T, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc. 2015; 90(3): 927-963.

[70] Rossler L, Lemburg S, Weitkamper A, et al. Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature. J Ultrasound. 2023; 26(4): 757-764.

[71] Wei H, Moffett JR, Amanat M, et al. The pathogenesis of, and pharmacological treatment for, Canavan disease. Drug Discov Today. 2022; 27(9): 2467-2483.

[72] Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta. 2010; 1801(8): 878-886.

[73] Vos M, Dulovic-Mahlow M, Mandik F, et al. Ceramide accumulation induces mitophagy and impairs beta-oxidation in PINK1 deficiency. Proc Natl Acad Sci USA. 2021; 118(43): e2025347118.

[74] Alves Conceicao C, Assis de Lemos G, Barros CA, Vieira T. What is the role of lipids in prion conversion and disease? Front Mol Neurosci. 2022; 15: 1032541.

[75] Magaye RR, Savira F, Hua Y, et al. The role of dihydrosphingolipids in disease. Cell Mol Life Sci. 2019; 76(6): 1107-1134.

[76] Rao RP, Yuan C, Allegood JC, et al. Ceramide transfer protein function is essential for normal oxidative stress response and lifespan. Proc Natl Acad Sci USA. 2007; 104(27): 11364-11369.

[77] Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem. 2003; 278(22): 19777-19783.

[78] Satoi H, Tomimoto H, Ohtani R, et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience. 2005; 130(3): 657-666.

[79] Gohil VM, Zhu L, Baker CD, et al. Meclizine inhibits mitochondrial respiration through direct targeting of cytosolic phosphoethanolamine metabolism. J Biol Chem. 2013; 288(49): 35387-35395.

[80] Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19(21): 5720-5728.

[81] Rockenfeller P, Koska M, Pietrocola F, et al. Phosphatidylethanolamine positively regulates autophagy and longevity. Cell Death Differ. 2015; 22(3): 499-508.

[82] Nair U, Yen WL, Mari M, et al. A role for Atg8-PE deconjugation in autophagosome biogenesis. Autophagy. 2012; 8(5): 780-793.

[83] Makarava N, Savtchenko R, Lasch P, Beekes M, Baskakov IV. Preserving prion strain identity upon replication of prions in vitro using recombinant prion protein. Acta Neuropathol Commun. 2018; 6(1): 92.

[84] Deleault NR, Piro JR, Walsh DJ, et al. Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci USA. 2012; 109(22): 8546-8551.

[85] Supattapone S. Phosphatidylethanolamine as a prion cofactor: potential implications for disease pathogenesis. Prion. 2012; 6(5): 417-419.

[86] Yan Q, Han C, Wang G, Waddington JL, Zheng L, Zhen X. Activation of AMPK/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency-sensitized dopaminergic neuronal death. Mol Pharmacol. 2017; 92(6): 640-652.

[87] Chen B, Teng Y, Zhang X, Lv X, Yin Y. Metformin alleviated aβ-induced apoptosis via the suppression of JNK MAPK signaling pathway in cultured hippocampal neurons. Biomed Res Int. 2016; 2016: 1421430.

[88] Ou Z, Kong X, Sun X, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. Brain Behav Immun. 2018; 69: 351-363.

[89] Xu X, Sun Y, Cen X, et al. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model. Protein Cell. 2021; 12(10): 769-787.

[90] Cecchini G. Function and structure of complex II of the respiratory chain. Annu Rev Biochem. 2003; 72: 77-109.

[91] Jeong JK, Park SY. Transcriptional regulation of specific protein 1 (SP1) by hypoxia-inducible factor 1 alpha (HIF-1α) leads to PRNP expression and neuroprotection from toxic prion peptide. Biochem Biophys Res Commun. 2012; 429(1-2): 93-98.

[92] Ferro A, Carbone E, Zhang J, et al. Short-term succinic acid treatment mitigates cerebellar mitochondrial OXPHOS dysfunction, neurodegeneration and ataxia in a Purkinje-specific spinocerebellar ataxia type 1 (SCA1) mouse model. PLoS One. 2017; 12(12): e0188425.

[93] Alvarez G, Ramos M, Ruiz F, Satrustegui J, Bogonez E. Pyruvate protection against beta-amyloid-induced neuronal death: role of mitochondrial redox state. J Neurosci Res. 2003; 73(2): 260-269.

[94] Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem. 2013; 288(18): 12967-12977.

[95] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018; 19(2): 121-135.

[96] Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010; 1804(3): 581-591.

[97] Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, et al. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014; 5(6): 374-389.

[98] Ala M, Ala M. Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next? ACS Pharmacol Transl Sci. 2021; 4(6): 1747-1770.

[99] Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007; 104(29): 12017-12022.

[100] Senoo N, Miyoshi N, Goto-Inoue N, et al. PGC-1alpha-mediated changes in phospholipid profiles of exercise-trained skeletal muscle. J Lipid Res. 2015; 56(12): 2286-2296.

[101] Pradas I, Rovira-Llopis S, Naudi A, et al. Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. Sci Rep. 2019; 9(1): 16033.

[102] Madiraju AK, Qiu Y, Perry RJ, et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. 2018; 24(9): 1384-1394.

[103] Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510(7506): 542-546.

[104] Bekdash RA. Choline, the brain and neurodegeneration: insights from epigenetics. Front Biosci. 2018; 23(6): 1113-1143.

[105] Velazquez R, Winslow W, Mifflin MA. Choline as a prevention for Alzheimer's disease. Aging. 2020; 12(3): 2026-2027.

[106] Velazquez R, Ferreira E, Knowles S, et al. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. Aging Cell. 2019; 18(6): e13037.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.